OBJECTIVE - The aim of the study is to estimate lost labor productivity costs of prostate cancer (PC) to patients and their spouses.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS - This study used a nationally representative database from the United States, the Medical Expenditure Panel Survey, to estimate lost productivity costs attributable to PC for patients and their spouses.
We used multivariate methods that controlled for sociodemographic factors and comorbid diseases. Sensitivity analyses were used to mitigate the tendency for prevalence rates to be underreported in surveys.
RESULTS - PC patients had an aggregate national annual lost productivity cost of $5.4 billion ($3601 per individual), whereas their spouses had an aggregate annual lost productivity cost of $3.0 billion ($4013 per individual).
CONCLUSIONS - These results enhance our knowledge of lost labor productivity costs of PC morbidity and may inform the management and treatment of PC from an employer's perspective.
Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine. 2016 Apr [Epub]
John A Rizzo, Teresa M Zyczynski, Jie Chen, Peter J Mallow, Géralyn C Trudel, John R Penrod
Stony Brook University (Dr Rizzo), Stony Brook, New York; Bristol-Myers Squibb (Dr Zyczynski and Dr Penrod), Princeton, New Jersey; University of Maryland School of Public Health (Dr Chen), College Park; CTI Clinical Trial and Consulting, Inc. (Dr Mallow), Cincinnati, Ohio; and Bristol-Myers Squibb (Dr Trudel), Montréal, Québec, Canada.